Trials / Completed
CompletedNCT00193622
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
A Phase II Trial of Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- SCRI Development Innovations, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site. Bevacizumab and erlotinib are relatively well-tolerated and have non-overlapping toxicity profiles. This trial will be one of the first clinical trials to evaluate a combination of targeted agents in the treatment of a solid tumor.
Detailed description
Upon determination of eligibility, patients will be receive: * Bevacizumab + Erlotinib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | |
| DRUG | Erlotinib |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-09-01
- Completion
- 2009-01-01
- First posted
- 2005-09-19
- Last updated
- 2010-09-17
Source: ClinicalTrials.gov record NCT00193622. Inclusion in this directory is not an endorsement.